BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 24518599)

  • 1. Prostate cancer bone metastases acquire resistance to androgen deprivation via WNT5A-mediated BMP-6 induction.
    Lee GT; Kang DI; Ha YS; Jung YS; Chung J; Min K; Kim TH; Moon KH; Chung JM; Lee DH; Kim WJ; Kim IY
    Br J Cancer; 2014 Mar; 110(6):1634-44. PubMed ID: 24518599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. WNT5A induces castration-resistant prostate cancer via CCL2 and tumour-infiltrating macrophages.
    Lee GT; Kwon SJ; Kim J; Kwon YS; Lee N; Hong JH; Jamieson C; Kim WJ; Kim IY
    Br J Cancer; 2018 Mar; 118(5):670-678. PubMed ID: 29381686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone morphogenetic protein-6 induces castration resistance in prostate cancer cells through tumor infiltrating macrophages.
    Lee GT; Jung YS; Ha YS; Kim JH; Kim WJ; Kim IY
    Cancer Sci; 2013 Aug; 104(8):1027-32. PubMed ID: 23710822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of WNT7B-induced noncanonical pathway in advanced prostate cancer.
    Zheng D; Decker KF; Zhou T; Chen J; Qi Z; Jacobs K; Weilbaecher KN; Corey E; Long F; Jia L
    Mol Cancer Res; 2013 May; 11(5):482-93. PubMed ID: 23386686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The lncRNA PTTG3P promotes the progression of CRPC via upregulating PTTG1.
    Huang S; Liao Q; Li W; Deng G; Jia M; Fang Q; Ji H; Meng M
    Bull Cancer; 2021 Apr; 108(4):359-368. PubMed ID: 33743960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen suppresses proliferation of castration-resistant LNCaP 104-R2 prostate cancer cells through androgen receptor, Skp2, and c-Myc.
    Chuu CP; Kokontis JM; Hiipakka RA; Fukuchi J; Lin HP; Lin CY; Huo C; Su LC; Liao S
    Cancer Sci; 2011 Nov; 102(11):2022-8. PubMed ID: 21781227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phospholipase C (PLC)ε Promotes Androgen Receptor Antagonist Resistance via the Bone Morphogenetic Protein (BMP)-6/SMAD Axis in a Castration-Resistant Prostate Cancer Cell Line.
    Yuan M; Gao Y; Li L; Sun W; Cheng H; Li T; Niu L; Du Z; Quan Z; Luo C; Wu X
    Med Sci Monit; 2019 Jun; 25():4438-4449. PubMed ID: 31201297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer.
    Dondoo TO; Fukumori T; Daizumoto K; Fukawa T; Kohzuki M; Kowada M; Kusuhara Y; Mori H; Nakatsuji H; Takahashi M; Kanayama HO
    Anticancer Res; 2017 Jan; 37(1):125-134. PubMed ID: 28011482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A simple prognostic model involving prostate-specific antigen, alkaline phosphatase and albumin for predicting the time required to progress to castration-resistant prostate cancer in patients who received androgen deprivation therapy.
    Lv W; Shang H; Pei X; Chen Y; Xie H; He D; Wang X; Li L
    Int Urol Nephrol; 2017 Jan; 49(1):61-67. PubMed ID: 27837416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Up-Regulation of LAT1 during Antiandrogen Therapy Contributes to Progression in Prostate Cancer Cells.
    Xu M; Sakamoto S; Matsushima J; Kimura T; Ueda T; Mizokami A; Kanai Y; Ichikawa T
    J Urol; 2016 May; 195(5):1588-1597. PubMed ID: 26682754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer.
    Chu FM; Sartor O; Gomella L; Rudo T; Somerville MC; Hereghty B; Manyak MJ
    Eur J Cancer; 2015 Aug; 51(12):1555-69. PubMed ID: 26048455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen-deprivation induced senescence in prostate cancer cells is permissive for the development of castration-resistance but susceptible to senolytic therapy.
    Carpenter V; Saleh T; Min Lee S; Murray G; Reed J; Souers A; Faber AC; Harada H; Gewirtz DA
    Biochem Pharmacol; 2021 Nov; 193():114765. PubMed ID: 34536356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo.
    Thomas C; Lamoureux F; Crafter C; Davies BR; Beraldi E; Fazli L; Kim S; Thaper D; Gleave ME; Zoubeidi A
    Mol Cancer Ther; 2013 Nov; 12(11):2342-55. PubMed ID: 23966621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PCSD1, a new patient-derived model of bone metastatic prostate cancer, is castrate-resistant in the bone-niche.
    Godebu E; Muldong M; Strasner A; Wu CN; Park SC; Woo JR; Ma W; Liss MA; Hirata T; Raheem O; Cacalano NA; Kulidjian AA; Jamieson CA
    J Transl Med; 2014 Oct; 12():275. PubMed ID: 25278011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microtubule-associated protein tau (MAPT) promotes bicalutamide resistance and is associated with survival in prostate cancer.
    Sekino Y; Han X; Babasaki T; Goto K; Inoue S; Hayashi T; Teishima J; Shiota M; Takeshima Y; Yasui W; Matsubara A
    Urol Oncol; 2020 Oct; 38(10):795.e1-795.e8. PubMed ID: 32430253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses.
    Armstrong AJ; Shore ND; Szmulewitz RZ; Petrylak DP; Holzbeierlein J; Villers A; Azad A; Alcaraz A; Alekseev B; Iguchi T; Gomez-Veiga F; Rosbrook B; Lee HJ; Haas GP; Stenzl A
    J Urol; 2021 May; 205(5):1361-1371. PubMed ID: 33356529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
    Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R
    J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Macrophages induce neuroendocrine differentiation of prostate cancer cells via BMP6-IL6 Loop.
    Lee GT; Kwon SJ; Lee JH; Jeon SS; Jang KT; Choi HY; Lee HM; Kim WJ; Lee DH; Kim IY
    Prostate; 2011 Oct; 71(14):1525-37. PubMed ID: 21374653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial.
    Penson DF; Armstrong AJ; Concepcion R; Agarwal N; Olsson C; Karsh L; Dunshee C; Wang F; Wu K; Krivoshik A; Phung D; Higano CS
    J Clin Oncol; 2016 Jun; 34(18):2098-106. PubMed ID: 26811535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.